Organizations Filed Purposes:
TRANSPOC CULTIVATES OPEN COLLABORATION AMONG A WIDE RANGE OF ONCOLOGY DRUG DISCOVERY ORGANIZATIONS, INCLUDING ACADEMIC AND MEDICAL INSTITUTIONS, EMERGING DRUG DISCOVERY COMPANIES, LARGE BIOPHARMACEUTICAL CORPORATIONS AND DISEASE-BASED FOUNDATIONS.
TRANSPOC IS A NOT-FOR-PROFIT SCIENTIFIC RESEARCH ORGANIZATION THAT WILL PROVIDE ITS SPONSORS WITH UNPRECEDENTED ACCESS TO DATA AND LARGE-SCALE TECHNOLOGIES TO ACCELERATE THE DISCOVERY OF BREAKTHROUGH CANCER MEDICINES. TRANSPOC CULTIVATES OPEN COLLABORATION AMONG A WIDE RANGE OF ONCOLOGY DRUG DISCOVERY ORGANIZATIONS, INCLUDING ACADEMIC AND MEDICAL INSTITUTIONS, EMERGING DRUG DISCOVERY COMPANIES, LARGE BIOPHARMACEUTICAL CORPORATIONS AND DISEASE-BASED FOUNDATIONS.TRANSPOC'S PURPOSE: PERFORM SCIENTIFIC RESEARCH THAT ENABLES THE ONCOLOGY FIELD TO DEVELOP AND DELIVER MORE EFFECTIVE PERSONALIZED THERAPIES TO PATIENTS. TO THAT END, TRANSPOC IS BUILDING SHARABLE, LARGE-SCALE, INTEGRATED AND CAPITAL-EFFICIENT TRANSLATIONAL ONCOLOGY PLATFORMS AND BIOINFORMATICS CAPABILITIES THAT ENABLE GREATER CLINICAL PROOF-OF-CONCEPT SUCCESS IN THE DEVELOPMENT OF NEW CANCER THERAPIES.GENETIC DIVERSITY IN HUMAN CANCERS PRESENTS A SIGNIFICANT CHALLENGE FOR THOSE DEVELOPING NEW TREATMENTS. ACTIVE COLLABORATION PROVIDES THE BEST POTENTIAL TO TRANSFORM THIS CHALLENGE INTO OPPORTUNITY.THE SUCCESS OF NEXT-GENERATION PRECISION CANCER MEDICINE IS DEPENDENT ON APPROPRIATELY DEFINING PATIENT POPULATIONS AND MATCHING THEM TO THE 'RIGHT' TREATMENTS FOR THEIR SPECIFIC CANCERS. GENETICALLY CHARACTERIZED CANCER CELL LINES AND PATIENT-DERIVED XENOGRAFT MODELS ARE EMERGING AS PROMISING PLATFORMS TO DRIVE THE DEVELOPMENT OF THE 'RIGHT' TREATMENT OPTIONS. WHILE THESE TECHNOLOGIES ALREADY EXIST, IT IS BEYOND THE REACH OF MOST COMPANIES TO DEVELOP AND MAINTAIN THEM IN-HOUSE AT A SCALE THAT IS COST EFFECTIVE AND SCIENTIFICALLY RELEVANT.TO ADDRESS THESE SCALE AND ACCESSIBILITY ISSUES, TRANSPOC'S RESEARCH PLATFORMS OFFER ACCESS TO SHARED GLOBAL TECHNOLOGY AND TRANSLATIONAL RESEARCH RESOURCES. THIS COLLABORATIVE APPROACH ENABLES ALL PARTICIPANTS, REGARDLESS OF SIZE, TO ACCESS TECHNOLOGIES CRITICAL FOR SUCCESSFUL PRECISION MEDICINE DEVELOPMENT IN A PRECOMPETITIVE SPACE.
Executives Listed on Filing
Total Salary includes financial earnings, benefits, and all related organization earnings listed on tax filing
| Name | Title | Hours Per Week | Total Salary |
|---|
| Takeshi Hamano | TREASURER | 1 | $0 |
| Yutaka Ishizaka | SECRETARY | 6 | $0 |
| Markus Warmuth | DIRECTOR, PRESIDENT | 5 | $0 |
| Josh Sommer | DIRECTOR | 0.1 | $0 |
| Stephen Friend | DIRECTOR | 0.1 | $0 |
Data for this page was sourced from XML published by IRS (
public 990 form dataset) from:
https://s3.amazonaws.com/irs-form-990/201543209349302159_public.xml